Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 90

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 90
---
 in the genomics consumables business was primarily driven by lower demand for the plasmids and protein product lines at two large customers, which more than offset increased demand for next generation sequencing products.  Lower demand in the academic and government end-markets reduced core sales in the protein consumables and in the flow cytometry and lab automation solutions businesses while in the filtration business, decreased demand in the energy-related end-market more than offset increased demand in the microelectronic end-market.  During the three-month period, year-over-year core sales increased in the microscopy and mass spectrometry businesses with increased demand for consumables.  The microscopy business also saw increased demand for equipment in the confocal product line. 

Operating Profit Performance

Operating profit margins decreased 150 basis points during the three-month period ended March 28, 2025 as compared to the comparable period of 2024.  

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were unfavorably impacted by:

•Lower first quarter 2025 core sales, the impact of product mix and the impact of reduced leverage in the segment’s operational and administrative cost structure - 250 basis points

•The incremental dilutive effect in 2025 of acquired businesses - 40 basis points

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were favorably impacted by:

•First quarter 2024 acquisition-related fair value adjustment to inventory - 140 basis points

Depreciation and amortization of intangible assets increased as a percentage of sales during the three-month period ended March 28, 2025, primarily as a result of the decrease in sales and the impact of acquisitions.  

DIAGNOSTICS

The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Diagnostics Selected Financial Data

 Three-Month Period Ended($ in millions)March 28, 2025March 29, 2024Sales$2,449 $2,527 Operating profit718 830 Depreciation100 97 Amortization of intangible assets48 48 Operating profit as a % of sales29.3 %32.8 %Depreciation as a % of sales4.1 %3.8 %Amortization as a % of sales2.0 %1.9 %

26

Sales Decline and